STOCK TITAN

Avadel Pharmaceuticals plc Ordinary Share - AVDL STOCK NEWS

Welcome to our dedicated page for Avadel Pharmaceuticals plc Ordinary Share news (Ticker: AVDL), a resource for investors and traders seeking the latest updates and insights on Avadel Pharmaceuticals plc Ordinary Share stock.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a specialty pharmaceutical company headquartered in Dublin, Ireland, with operations in St. Louis, Missouri, and Lyon, France. The company focuses on developing, identifying, and commercializing differentiated pharmaceutical products designed to be safe, effective, and easy to administer, thereby improving patient adherence and outcomes. Avadel's products primarily target the urology, central nervous system (CNS) / sleep, and hospital markets.

One of Avadel's flagship products is LUMRYZ™, an extended-release formulation of sodium oxybate, approved by the U.S. Food & Drug Administration (FDA) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. LUMRYZ is notable for its once-at-bedtime dosing, which eliminates the need for a middle-of-the-night dose, making it more convenient for patients.

The FDA granted LUMRYZ seven years of Orphan Drug Exclusivity, recognizing it as a major contribution to patient care over existing therapies. The approval was supported by results from the REST-ON trial, a Phase 3 study that demonstrated significant improvements in EDS, the Clinician Global Impression of Improvement (CGI-I), and reduced the frequency of cataplexy attacks.

Avadel recently announced its financial results for the third quarter ended September 30, 2023, reporting $7.0 million in net product revenue from LUMRYZ sales. The company has seen robust demand and positive feedback from the narcolepsy community, healthcare providers, and payers. Notably, CVS Health has moved LUMRYZ to preferred status starting January 1, 2024. Avadel also filed a supplemental NDA to extend LUMRYZ's indication to pediatric patients with narcolepsy, further expanding its market reach.

Financially, Avadel reported a net loss of $36.3 million for the quarter, driven by higher selling, general, and administrative expenses related to the LUMRYZ launch. Despite these challenges, the company maintains a strong cash position of $153.2 million as of September 30, 2023.

Looking ahead, Avadel plans to issue its Annual Report on Form 10-K for the year ended December 31, 2023, on February 29, 2024. The company continues to focus on expanding its product pipeline, including initiating a Phase 3 trial for idiopathic hypersomnia and optimizing commercial execution for LUMRYZ.

Rhea-AI Summary

Avadel Pharmaceuticals submitted an amendment on March 1, 2023, to the FDA seeking final approval for LUMRYZ, an investigational treatment for cataplexy and excessive daytime sleepiness in adults with narcolepsy. This follows a favorable ruling by the Fed Circuit on February 24, which ordered Jazz Pharmaceuticals to delist a patent affecting LUMRYZ. The company estimates a potential patient population exceeding 30,000, with an annual market opportunity over $3 billion, given current market dynamics. LUMRYZ previously received tentative FDA approval in July 2022, and its unique formulation aims to improve patient adherence compared to existing therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
-
Rhea-AI Summary

Dublin, Ireland, Feb. 16, 2023 – Avadel Pharmaceuticals (Nasdaq: AVDL) announced the grant of non-statutory options for 28,000 ordinary shares to two new employees as part of its 2021 Inducement Plan. The options, which have a ten-year term and vest over four years, were awarded to incentivize the new hires in compliance with Nasdaq Listing Rule 5635(c)(4). Avadel is focused on transforming medicines, with its lead candidate, LUMRYZ™, targeting narcolepsy through innovative drug delivery technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
none
-
Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) has announced that its management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 1:00 p.m. ET. A live webcast and archived recording of the chat will be accessible on Avadel’s Investor Relations website for 90 days post-conference. Avadel is focused on innovative biopharmaceutical solutions, particularly an investigational sodium oxybate formulation aimed at treating cataplexy and excessive daytime sleepiness in adults with narcolepsy. For further details, visit www.avadel.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
conferences
Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced on February 3, 2023, the approval from its Compensation Committee to grant non-statutory options for 38,000 ordinary shares to two new employees. This move is in line with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize the new hires as part of the 2021 Inducement Plan. The options will have a ten-year term and vest gradually over four years, starting with 25% vesting on the first anniversary. Avadel focuses on innovative solutions for medicine and is known for its investigational drug, LUMRYZ™, aimed at treating narcolepsy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
-
Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) has published significant real-world data on the adverse events linked to dosing errors of immediate-release oxybate. The study reveals that of 541 reports analyzed, 177 were serious, with 41 cases resulting in adverse events due to early second dose intake. Notably, 22% required emergency services and 27% led to hospitalizations, highlighting the risks of the current dosing schedule. The analysis calls for greater awareness among medical professionals and patients, as current labeling lacks information on these risks. The company suggests that an upcoming once-nightly formulation could potentially mitigate these dosing errors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.86%
Tags
none
-
Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced the approval of non-statutory options by its Compensation Committee to three new employees. The aggregate of 40,500 ordinary shares will be granted under Avadel's 2021 Inducement Plan. These options come with a ten-year term and will vest over four years, with the first 25% vesting on the one-year anniversary. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent joining the biopharmaceutical company focused on innovative medication solutions, including its lead drug candidate, LUMRYZ™.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.86%
Tags
none
Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced the grant of non-statutory options to six new employees, allowing them to purchase 105,000 ordinary shares under the 2021 Inducement Plan. This decision was made by the Compensation Committee and is in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary of employment. This initiative is aimed at attracting talent while adhering to regulatory requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
none
-
Rhea-AI Summary

Acadia Pharmaceuticals has appointed Dr. Doug Williamson as Executive Vice President, Head of Research and Development. Dr. Williamson, succeeding Dr. Srdjan Stankovic, brings over 20 years of neuroscience R&D experience, most recently serving as Chief Medical Officer at Avadel Pharmaceuticals. His leadership is expected to play a crucial role as Acadia prepares for the potential approval of trofinetide for Rett syndrome and advances its clinical programs. This strategic move aims to strengthen Acadia's position in the neuroscience market during a pivotal time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
management
-
Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced the grant of non-statutory options for 30,000 shares to a new employee as part of its 2021 Inducement Plan. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent on the employee's continued service. This grant complies with Nasdaq Listing Rule 5635(c)(4). Avadel is focused on innovative medication development, including its lead candidate LUMRYZ™, an investigational treatment for narcolepsy. For further information, visit www.avadel.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.2%
Tags
none
Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced its participation in two upcoming investor conferences. Management will engage in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29 at 3:30 p.m. ET, and at the Evercore ISI HealthCONx Conference on December 1 at 2:40 PM ET. Live webcasts and archived recordings will be accessible on Avadel’s Investor Relations website for 90 days post-conference. Avadel focuses on innovative treatments like LUMRYZ™, aimed at addressing narcolepsy symptoms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
conferences

FAQ

What is the current stock price of Avadel Pharmaceuticals plc Ordinary Share (AVDL)?

The current stock price of Avadel Pharmaceuticals plc Ordinary Share (AVDL) is $10.31 as of December 20, 2024.

What is the market cap of Avadel Pharmaceuticals plc Ordinary Share (AVDL)?

The market cap of Avadel Pharmaceuticals plc Ordinary Share (AVDL) is approximately 980.5M.

What is Avadel Pharmaceuticals plc?

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a specialty pharmaceutical company focused on developing differentiated pharmaceutical products for urology, CNS/sleep, and hospital markets.

What is LUMRYZ?

LUMRYZ is an extended-release formulation of sodium oxybate, approved by the FDA for treating cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. It is taken once at bedtime.

Where is Avadel Pharmaceuticals headquartered?

Avadel Pharmaceuticals is headquartered in Dublin, Ireland, with additional operations in St. Louis, Missouri, and Lyon, France.

What recent financial results did Avadel report?

For the third quarter ended September 30, 2023, Avadel reported $7.0 million in net product revenue from LUMRYZ sales and a net loss of $36.3 million.

What distinguishes LUMRYZ from other treatments?

LUMRYZ is the first and only once-at-bedtime oxybate treatment for narcolepsy, offering a more convenient dosing regimen compared to twice-nightly oxybate products.

What are the most common side effects of LUMRYZ?

The most common side effects include nausea, dizziness, bedwetting, headache, and vomiting.

What is the significance of LUMRYZ's Orphan Drug Exclusivity?

The FDA granted LUMRYZ seven years of Orphan Drug Exclusivity due to its significant contribution to patient care, providing a once-nightly dosing alternative to existing treatments.

How did the narcolepsy community respond to the launch of LUMRYZ?

The launch received overwhelmingly positive feedback, with early patient demand and significant support from healthcare providers and payers.

What other areas does Avadel Pharmaceuticals focus on?

In addition to narcolepsy, Avadel focuses on developing treatments for urology and hospital markets.

What are Avadel’s future plans for LUMRYZ?

Avadel plans to expand LUMRYZ's indication to pediatric patients and continue its Phase 3 trials for idiopathic hypersomnia.

Avadel Pharmaceuticals plc Ordinary Share

Nasdaq:AVDL

AVDL Rankings

AVDL Stock Data

980.48M
91.76M
4.77%
80.29%
9.15%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
DUBLIN